Breaking News on Pharmaceutical Technology

Latest news headlines

Products

Suppliers

ZaCh Systems acquires fine chemicals unit

18-Sep-2007 - ZaCh Systems has acquired PPG Industries' fine chemicals business for approximately $65m (€46.9m), which includes a pharmaceutical fine chemicals facility in Texas.

All change at BioProgress

17-Sep-2007 - UK tabletting specialist BioProgress made a series of announcements last week, not only landing itself a commercial partner and patent protection for its novel tablet coating technology, but also rebranding itself under a new name, Meldex International.

Soma 250mg dose gets approval

17-Sep-2007 - Swedish speciality pharma company Meda AB has announced its new low dose of Soma (carisoprodol) has been approved by the US Food and Drugs Administration (FDA).

Aspartame safe, study says

13-Sep-2007 - A new report looking at the safety of aspartame has concluded there is "no credible evidence" the sweetener is unsafe.

Wyeth backs Flamel drug delivery tech

13-Sep-2007 - Wyeth has signed a license agreement with French firm Flamel Technologies to apply the company's second innovative drug delivery technology to one of its protein therapeutics.

Innocoll and TGR collaborate to develop wound healer

12-Sep-2007 - Innocoll Technologies has announced collaboration with Australian-based TGR BioSciences to combine Innocoll's drug delivery technology with TGR's bioactive wound healing protein.

Another plant bites the dust

12-Sep-2007 - Yet another production site has fallen to the unrelenting axe of big pharma's consolidation drive as Pfizer announces that its only UK manufacturing plant is to be closed down.

Biotest scoops up ailing Nabi's biologics unit

11-Sep-2007 - German firm Biotest has bought up Nabi Biopharmaceuticals biologics division in a multi-million Euro deal, less than three months after the unit was created following Nabi restructuring efforts.

SkyePharma's Flutiform progresses through red tape

11-Sep-2007 - SkyePharma is moving forward with its asthma treatment Flutiform following talks with the US Food and Drug Administration (FDA) on an agreed approach for additional clinical data that had been requested.

Colorcon takes on Chr. Hansen's excipient and coating division

10-Sep-2007 - Denmark-based Chr. Hansen has sold its excipients and coating division to US company Colorcon for an undisclosed sum to concentrate on its food business.

Aurobindo gets API facility approval

10-Sep-2007 - Indian company Aurobindo Pharma has received UK approval on its active pharmaceutical ingredient (API) facility in Kazipally.

PURE gets cGMP manufacturing approval

06-Sep-2007 - PURE Bioscience has received the two thumbs up for its manufacturing facility of a new molecular entity which is being explored as an antibacterial, antiviral and antifungal pharmaceutical.

Eden's bio garden grows

05-Sep-2007 - Britain's Eden Biodesign has been selected by Cancer Research UK as the beneficiary of two new biomanufacturing contracts as its biomanufacturing business continues to grow.

Millipore targets arthritis research efficiency

04-Sep-2007 - Millipore has released a new kit that allows researchers to quickly generate arthritis mouse models for screening and evaluating anti-inflammatory therapeutics.

Abbott and AstraZeneca combine cholesterol drugs

04-Sep-2007 - Abbott and AstraZeneca are the latest pharmaceutical companies to take on the $21.6bn (€15.8bn) cholesterol market with a combination drug.

Boehringer Ingelheim recalls clobutinol products

03-Sep-2007 - Boehringer Ingelheim is voluntarily recalling all worldwide products containing clobutinol hydrochloride, which has been on the market for 46 years, following a report questioning the drug's safety.

Pseudoephedrine drugs still OTC

03-Sep-2007 - Reformulations of pseudoephedrine- and ephedrine-containing drugs in the UK look unlikely following the announcement of less extreme restrictions on the sale of the pharmaceuticals.

Six-month prostate cancer drug soon to be launched

03-Sep-2007 - A six-month formulation of a prostate cancer drug will soon be launched in 23 European countries following its successful approval procedure.

Patent changes and the pharma industry

30-Aug-2007 - Pharmaceutical companies are being urged to develop strategies in an effort to deal with the controversial new patent rules that come into force in the US in November.

SAFC Wisconsin site keeps on growing

30-Aug-2007 - In the latest phase of growth at chemical firm SAFC's flagship high potency active pharmaceutical ingredients (HPAPIs) facility in Madison, Wisconsin, the site will be treated to another multi-million dollar expansion and new analytical testing equipment.

EU approval of new Rebif just what the doctor ordered

30-Aug-2007 - Merck Serono's new and improved version of its blockbuster multiple sclerosis (MS) drug Rebif (interferon beta-1a) has been approved in the EU, providing a little added protection to the company's MS franchise.

AstraZeneca's schizophrenia drug gets the nod in the Netherlands

30-Aug-2007 - AstraZeneca has had its new extended-release formulation of its schizophrenia drug approved in the Netherlands.

FDA considers combo allergy pill

29-Aug-2007 - A single tablet formulation combining two major allergy treatments has been accepted for review by the US Food and Drug Administration (FDA).

Octreotide prolonged release form ticking all the boxes

29-Aug-2007 - Results from a Phase II study of a prolonged release formulation of octreotide look encouraging for the treatment of acromegaly, according to Ambrilia Biopharma.

New plant fills the gap at Aesica

23-Aug-2007 - A new pilot plant at UK firm Aesica's Cramlington site has filled a void in the active pharmaceutical ingredient (API) specialist's offering, allowing them to provide services all the way from Phase I through to product launch.

Sign up for your free newsletter